Oncology

Landmark Phase 3 trial shows TECVAYLI dramatically improves survival in early relapse, poised to become a new standard of care for multiple myeloma.

Celebrating two decades of innovation, RadioMedix unveils promising new alpha therapy data for pancreatic cancer at the SNMMI 2026 annual meeting.

With a new CMO who has a drug approval under his belt, ImmunoGenesis is poised to advance its novel therapy for hard-to-treat 'cold' tumors.

A novel drug aims to starve deadly brain tumors by rewiring their metabolism. BPGbio's upcoming ASCO update could signal a major shift for glioblastoma.

The oncology AI firm's new funding will expand its platform, which helps top cancer centers make sense of complex patient data and improve trial matching.

PeproMene Bio’s PMB-CT01 offers new hope, achieving a 78% complete response rate with a remarkable safety profile in hard-to-treat lymphoma patients.

BeOne Medicines' immunotherapy TEVIMBRA gains key reimbursement nods, paving the way for Canada's first funded option for a rare head and neck cancer.

Therini Bio's novel drug THN391 enters trials, targeting inflammation in diabetic eye disease, while a next-gen combo therapy aims to redefine care.

EOM Pharmaceutical gets FDA clearance for a trial on EOM613, a potential first-in-class treatment for cancer cachexia, a severe wasting syndrome.

With late-stage trials for its revolutionary eye and lung disease treatments, 4DMT must convince investors its focused, high-stakes strategy will pay off.

NEOK Bio begins Phase 1 trials for two bispecific ADCs, a next-gen therapy aiming to outsmart tumor resistance and offer new hope for solid tumor patients.

New preclinical data shows RTY-406 could be a first-in-class therapy for PSC, a progressive liver disease with no effective treatments.

Free skin cancer screenings in Ottawa highlight a national health crisis as wait times soar and experts demand urgent government action on specialist care.

A new partnership between TD2 Oncology and Panome Bio aims to merge clinical expertise with deep multi-omics data to accelerate personalized cancer therapies.

Vanda Pharmaceuticals' rare disease drug gets a key designation in Japan, unlocking major incentives and promising a new treatment for a severe skin disease.

With CHF 105 million in new funding, NUCLIDIUM is advancing its novel copper-based radiotheranostics for metastatic prostate and breast cancer.

A landmark approval paves the way for a 200-bed cancer hospital in Nepal's most underserved province, promising hope and advanced care to millions.

John Theurer Cancer Center presents breakthroughs in CAR-T, ADCs, and health equity at ASCO, offering new hope for patients worldwide.

Ionetix wins FDA approval for its generic prostate cancer imaging agent, a move set to boost access and shake up the competitive radiopharmaceutical market.

Following its X3D acquisition, Catalyst MedTech unveils an expanded portfolio and a new strategy to tackle aging equipment and modernize nuclear medicine.